VERA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
VERA THERAPEUTICS INC. - More news...
VERA THERAPEUTICS INC. - More news...
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
- Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
- Vera Therapeutics to Participate at Upcoming Investor Conferences
- Vera Therapeutics to Participate at Upcoming Investor Conferences
- Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
- Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
- Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics to Participate at September Investor Conferences
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
